Skip to content

A study to evaluate the performance of Furocyst in patients with Poly Cystic Ovary Syndrome Patients

Evaluating the performance of Furocyst in patients with Poly Cystic Ovary Syndrome Patients

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/06/008748
Enrollment
370
Registered
2017-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome Health Condition 2: null- Polycystic ovary syndrome (PCOS)

Interventions

Intervention1: furocyst group: furocyst pills will be given twice a day for 3 months. Furocyst is Fenugreek seed extract Control Intervention1: control group: placebo will be provided twice a day for

Sponsors

CHERESO Chemical resources
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with PCOS by Rottadom Criteria Premenopausal women between 18to 45 years of age BMI BMI less than 42 Physician approval for selected patient Willingness to provide informed consent and to visit hospital for follow up Adequate hepatic renal Cardiac and hematological functions

Exclusion criteria

Exclusion criteria: Pregnant or lactating women with infants less than 1year old Any pre existing condition or contraindications like CAD abnormal creatinine levels liver dysfunction Bedridden patients and patients due for operations Enrolled in other active intervention research studies Post menopausal women Women with hysterectomy Hyperprolactinemia Patients with congenital adrenal hyperplasia. Patients suffering from Cushingââ?¬•s syndrome. Uncontrolled Hypertensive or known Diabetics on drugs Smoking or drug addicts or with psychiatric illness Patients diagnosed with androgen secreting tumors Patients with Hypogonadotropic and Hypogonadism

Design outcomes

Primary

MeasureTime frame
Anthropometric factors USG - ovarian volume and the number of ovarian cysts Timepoint: Baseline mid intervention 1.5 months post intervention 3 months

Secondary

MeasureTime frame
Anthropometric factors Weight BMI Reproductive factors Menstrual regularity (an initiation of menses or significant shortening of cycle length where possible) Clinical hyperandrogenism Ferriman-Gallwey score Metabolic factor Hormonal assay, Fasting glucose, OGTT, Insulin resistance LFT RFTTimepoint: Baseline mid intervention 1.5 months post intervention 3 months

Countries

India

Contacts

Public ContactDr Amarjeet Singh

PGIMER Chandigarh

dramarjeet56@gmail.com9814472226

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026